US › Healthcare

Immuron Ltd ADR (IMRN)

US · Healthcare · Biotechnology

$1.18-0.84%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$3.6M

Revenue YoY

-10.4%

Net profit

$-1.9M

EPS

$0.00

EPS estimate

$0.00

Net margin

-54.4%

Key statistics

Market cap

$9.6M

Forward P/E

0.0

P/B

1.28

Book value

$0.97

EPS (TTM)

$-0.37

52-week high

$2.39

52-week low

$0.68

50-day MA

$1.20

200-day MA

$1.02

Beta

0.52

Analyst view

Analysts rate Immuron Ltd ADR a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $4.01.

Shareholding

Institutions

0.97%

Largest institutional holders

Fund	Stake
Citadel Advisors Llc	0.53%
Morgan Stanley - Brokerage Accounts	0.38%
XTX Topco Ltd	0.22%
TWO SIGMA SECURITIES, LLC	0.14%
Rhumbline Advisers	0.09%
BNP Paribas Arbitrage, SA	0.06%
BlackRock Inc	0.00%
Jane Street Group LLC	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Immuron Ltd ADR — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.